急性胆囊炎市场－全球产业规模、份额、趋势、机会及预测（按类型、原因、诊断程序、治疗方法、最终用户、地区和竞争格局划分），2021-2031年

全球急性胆囊炎市场预计将从2025年的26.4亿美元成长到2031年的37.3亿美元，复合年增长率（CAGR）为5.93%。这一增长主要受急性胆囊炎治疗需求的推动。急性胆囊炎是由胆结石引起的胆囊管阻塞所致，需要紧急诊断和治疗。市场扩张很大程度上是由于胆结石发生率的上升，胆结石的发生率上升与全球人口老化和肥胖率上升密切相关。此外，微创手术（如腹腔镜胆囊切除术和机器人辅助胆囊切除术）的广泛应用也有助于患者復原。

然而，限制市场效率的一大障碍是标准影像检查结果经常存在歧义，这可能导致治疗延误和併发症风险增加。早期诊断的不确定性造成了医疗连续性方面的重大缺口。美国感染疾病学会 (IDSA) 的一项案例研究凸显了这个问题：2024 年，腹部超音波对疑似急性胆囊炎病例的中位敏感性仅为 73%。此类数据强调了迫切需要能够克服当前标准影像检查通讯协定局限性的更先进的诊断技术。

市场驱动因素

市场收入的主要驱动因素是胆结石及相关疾病盛行率的不断上升，这直接导致全球胆囊切除术数量的增加。生活方式的改变和人口趋势，尤其是肥胖，进一步推动了这一趋势，使更多人群易患胆道疾病，并迫使医疗系统扩大其急诊护理能力。根据美国国立卫生研究院 (NIH) 于 2025 年 10 月发布的题为《2000-2024 年全球普通人群胆结石率估计》的系统性综述，全球胆结石率估计为 5.86%，这确保了对急诊护理的稳定需求，并为市场的长期稳定需求奠定了基础。

同时，腹腔镜和机器人辅助胆囊切除术的兴起正在重塑医疗领域，并透过引入先进的手术器械推动市场价值的成长。这些微创技术如今已成为黄金标准，由于住院时间缩短和併发症发生率降低，手术量显着增加。例如，Intuitive Surgical公司于2025年1月发布的「2024年第四季及全年初步快报」显示，使用达文西手术系统进行的手术数量年增17%。然而，经济挑战依然存在。美国外科医学会（ACS）2025年4月的研究发现，机器人胆囊切除术的耗材成本显着高于传统腹腔镜手术，分别为1,309美元和534美元。这凸显了常用标准手术与采用高附加价值技术的介入手术之间的市场分化。

市场挑战

全球急性胆囊炎市场的主要限制因素是传统影像技术固有的诊断不确定性。早期诊断准确性的不足造成了患者照护的瓶颈，并常常导致医生对是否需要紧急手术犹豫不决。当腹部超音波等关键诊断工具提供不确定结果时，医生通常会选择保守治疗而非胆囊切除术。这会延误手术（该市场的主要收入来源），并因患者住院时间延长而加重医疗资源的负担。

这种诊断上的不确定性导致许多患者最初因检查结果不确定而接受非手术治疗，最终治疗失败率很高。根据美国外科医师学会2024年的数据，78%因急性胆囊炎症状而未接受手术便出院的患者最终需要紧急入院接受胆囊切除术。这一趋势凸显了市场效率低下的一个显着问题：初次就诊时未能准确诊断和治疗会导致医疗服务碎片化，错失治疗良机，从而阻碍手术治疗方案的顺利推广和整体市场增长。

市场趋势

一个值得关注的趋势是超音波引导下胆囊引流术（EUS-GBD）的兴起，特别是腔内金属支架（LAMS）的应用，为不合格手术的患者提供了一种创新方法。该技术为经皮胆囊造瘻术提供了一种微创替代方案，适用于高风险老年患者和合併多种疾病、无法耐受标准胆囊切除术的患者，透过提供内部引流来改善患者的生活品质。 2024年2月发表于《诊断学》（Diagnostics）杂誌的一项题为“使用腔内压迫金属支架进行EUS引导下胆囊引流治疗急性胆囊炎”的研究支持了该技术的有效性，该研究报告称，在高风险患者中，LAMS置入的技术成功率高达94%，使其成为一种有效的标准治疗方法。

同时，人工智慧（AI）在诊断影像中的应用正在克服传统超音波的局限性，并为早期精准检测树立新的标准。利用机器学习实现病灶辨识和胆囊分割的自动化，能够帮助医疗服务提供者减少操作者间的差异，并弥补传统影像技术灵敏度低的不足，从而加快干预决策。发表于2024年2月《生物医学科学与技术研究期刊》（Biomedical Journal of Scientific & Technical Research）的一项题为「基于人工智慧的胆囊分割技术在急性胆囊炎诊断中的应用」的研究表明，应用特定的AI模型可实现84.09%的诊断准确率，使其成为灵敏度不足的超音波的理想敏感性。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球急性胆囊炎市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（结石性急性胆囊炎与非结石性急性胆囊炎）
  • 依病因分类（胆结石、肿瘤、胆管阻塞、微生物感染、其他）
  • 透过诊断程序（超音波、胆道闪烁显像、 电脑断层扫描、ERCP（内视镜逆行性胰造影）、其他）
  • 依治疗方法（手术与非手术）
  • 依最终使用者（医院/诊所、门诊手术中心、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美急性胆囊炎市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲急性胆囊炎市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区急性胆囊炎市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲急性胆囊炎市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲急性胆囊炎市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球急性胆囊炎市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Boston Scientific Corporation
• Fresenius Kabi AG
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Limited
• Merck & Co. Inc.
• Becton, Dickinson and Company
• Simulab Corporation
• AbbVie Inc.
• Fortimedix Surgical BV

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Acute Cholecystitis Market is projected to expand from USD 2.64 Billion in 2025 to USD 3.73 Billion by 2031, reflecting a CAGR of 5.93%. This growth is rooted in the management of acute gallbladder inflammation, a condition primarily triggered by gallstone obstruction of the cystic duct that necessitates urgent diagnosis and treatment. Market expansion is heavily influenced by the escalating incidence of gallstone disease, which is closely tied to an aging global demographic and rising obesity rates, alongside the broader application of minimally invasive surgical options like laparoscopic and robotic cholecystectomy that enhance patient recovery.

Conversely, a significant hurdle limiting market efficiency is the ambiguity often found in standard imaging results, which can result in treatment delays and higher complication risks. This lack of initial diagnostic clarity represents a substantial gap in the care continuum. Highlighting this issue, the Infectious Diseases Society of America reported in 2024 that the median sensitivity of abdominal ultrasound for detecting suspected acute cholecystitis was only 73%. Such data emphasizes the critical need for superior diagnostic technologies to surpass the constraints of current standard imaging protocols.

Market Driver

The primary catalyst for market revenue is the growing prevalence of gallstones and related disorders, which directly fuels the global volume of cholecystectomy surgeries. This momentum is further accelerated by lifestyle changes and demographic trends, specifically obesity, which make larger populations susceptible to biliary issues, thereby forcing healthcare systems to expand their acute management capacities. As noted by the National Institutes of Health in an October 2025 systematic review titled 'Estimating global prevalence of gallbladder stones in general population from 2000 to 2024,' the global prevalence of gallstones was determined to be 5.86%, ensuring a steady demand for acute care and underpinning long-term market stability.

In parallel, the shift toward laparoscopic and robotic cholecystectomy is redefining the therapeutic sector, increasing market value through the deployment of sophisticated surgical tools. These minimally invasive methods are now the gold standard due to their ability to shorten hospital stays and lower complication rates, which facilitates higher procedural volume. For instance, Intuitive Surgical's 'Preliminary Fourth Quarter and Full Year 2024 Results' from January 2025 indicated a 17% year-over-year increase in procedures using da Vinci systems. However, economic considerations persist; an April 2025 American College of Surgeons study revealed that robotic cholecystectomy involves significantly higher disposable costs at $1,309 compared to $534 for traditional laparoscopic methods, delineating a market split between high-volume standard care and premium technological interventions.

Market Challenge

The primary obstacle restricting the Global Acute Cholecystitis Market is the diagnostic uncertainty inherent in conventional imaging techniques. This lack of early precision forms a bottleneck in patient care, frequently leading to hesitation regarding the need for immediate surgery. When primary diagnostic tools like abdominal ultrasound fail to yield clear results, physicians often default to conservative management instead of performing a cholecystectomy, delaying the market's primary revenue-generating procedure and straining healthcare resources through extended hospitalizations.

The consequences of this diagnostic ambiguity are manifested in high treatment failure rates among patients initially treated non-surgically due to inconclusive tests. Data from the American College of Surgeons in 2024 showed that 78% of patients with acute cholecystitis symptoms who were discharged without surgery eventually required emergency readmission for a cholecystectomy. This pattern highlights a major market inefficiency, where the failure to accurately diagnose and treat the condition during the initial visit results in fragmented care and missed therapeutic opportunities, thereby hindering the seamless adoption of surgical solutions and overall market growth.

Market Trends

A significant trend is the rise of Endoscopic Ultrasound-Guided Gallbladder Drainage (EUS-GBD), specifically using Lumen-Apposing Metal Stents (LAMS), as a transformative approach for patients ineligible for surgery. This technique provides a minimally invasive substitute for percutaneous cholecystostomy, catering to high-risk elderly or comorbid patients unable to tolerate standard cholecystectomy, thereby improving quality of life by internalizing drainage. Validating this approach, a February 2024 study in Diagnostics titled 'EUS-Guided Gallbladder Drainage Using a Lumen-Apposing Metal Stent for Acute Cholecystitis' reported a 94% technical success rate for LAMS placement in high-risk groups, establishing it as an effective therapeutic standard.

Concurrently, the incorporation of Artificial Intelligence (AI) into diagnostic imaging is setting new benchmarks for early and precise detection, addressing the shortcomings of traditional ultrasound. By utilizing machine learning to automate pathology recognition and gallbladder segmentation, medical providers can mitigate inter-operator variability and the low sensitivity associated with standard imaging, facilitating quicker intervention decisions. As reported in the Biomedical Journal of Scientific & Technical Research in February 2024, the application of specific AI models in the study 'Usage of Artificial Intelligence in Gallbladder Segmentation to Diagnose Acute Cholecystitis' achieved a diagnostic accuracy of 84.09%, presenting a superior alternative to the lower sensitivity found in manual ultrasonography.

Key Market Players

• Boston Scientific Corporation
• Fresenius Kabi AG
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Limited
• Merck & Co. Inc.
• Becton, Dickinson and Company
• Simulab Corporation
• AbbVie Inc.
• Fortimedix Surgical BV

Report Scope

In this report, the Global Acute Cholecystitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Cholecystitis Market, By Type

• Calculous Acute Cholecystitis v/s Acalculous Acute Cholecystitis

Acute Cholecystitis Market, By Cause

• Gall Bladder Stones
• Tumor
• Bile Duct Blockage
• Microbial Infection
• Others

Acute Cholecystitis Market, By Diagnostic Procedure

• Ultrasonography
• Cholescintigraphy
• CT Scan
• ERCP (Endoscopic Retrograde Cholangiopancreatography)
• Others

Acute Cholecystitis Market, By Treatment

• Surgical v/s Non-Surgical

Acute Cholecystitis Market, By End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Acute Cholecystitis Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acute Cholecystitis Market.

Available Customizations:

Global Acute Cholecystitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acute Cholecystitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Calculous Acute Cholecystitis v/s Acalculous Acute Cholecystitis)
  • 5.2.2. By Cause (Gall Bladder Stones, Tumor, Bile Duct Blockage, Microbial Infection, Others)
  • 5.2.3. By Diagnostic Procedure (Ultrasonography, Cholescintigraphy, CT Scan, ERCP (Endoscopic Retrograde Cholangiopancreatography), Others)
  • 5.2.4. By Treatment (Surgical v/s Non-Surgical)
  • 5.2.5. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Acute Cholecystitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Cause
  • 6.2.3. By Diagnostic Procedure
  • 6.2.4. By Treatment
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Acute Cholecystitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Cause
      • 6.3.1.2.3. By Diagnostic Procedure
      • 6.3.1.2.4. By Treatment
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Acute Cholecystitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Cause
      • 6.3.2.2.3. By Diagnostic Procedure
      • 6.3.2.2.4. By Treatment
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Acute Cholecystitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Cause
      • 6.3.3.2.3. By Diagnostic Procedure
      • 6.3.3.2.4. By Treatment
      • 6.3.3.2.5. By End User

7. Europe Acute Cholecystitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Cause
  • 7.2.3. By Diagnostic Procedure
  • 7.2.4. By Treatment
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Acute Cholecystitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Cause
      • 7.3.1.2.3. By Diagnostic Procedure
      • 7.3.1.2.4. By Treatment
      • 7.3.1.2.5. By End User
  • 7.3.2. France Acute Cholecystitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Cause
      • 7.3.2.2.3. By Diagnostic Procedure
      • 7.3.2.2.4. By Treatment
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Acute Cholecystitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Cause
      • 7.3.3.2.3. By Diagnostic Procedure
      • 7.3.3.2.4. By Treatment
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Acute Cholecystitis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Cause
      • 7.3.4.2.3. By Diagnostic Procedure
      • 7.3.4.2.4. By Treatment
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Acute Cholecystitis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Cause
      • 7.3.5.2.3. By Diagnostic Procedure
      • 7.3.5.2.4. By Treatment
      • 7.3.5.2.5. By End User

8. Asia Pacific Acute Cholecystitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Cause
  • 8.2.3. By Diagnostic Procedure
  • 8.2.4. By Treatment
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Acute Cholecystitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Cause
      • 8.3.1.2.3. By Diagnostic Procedure
      • 8.3.1.2.4. By Treatment
      • 8.3.1.2.5. By End User
  • 8.3.2. India Acute Cholecystitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Cause
      • 8.3.2.2.3. By Diagnostic Procedure
      • 8.3.2.2.4. By Treatment
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Acute Cholecystitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Cause
      • 8.3.3.2.3. By Diagnostic Procedure
      • 8.3.3.2.4. By Treatment
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Acute Cholecystitis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Cause
      • 8.3.4.2.3. By Diagnostic Procedure
      • 8.3.4.2.4. By Treatment
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Acute Cholecystitis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Cause
      • 8.3.5.2.3. By Diagnostic Procedure
      • 8.3.5.2.4. By Treatment
      • 8.3.5.2.5. By End User

9. Middle East & Africa Acute Cholecystitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Cause
  • 9.2.3. By Diagnostic Procedure
  • 9.2.4. By Treatment
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Acute Cholecystitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Cause
      • 9.3.1.2.3. By Diagnostic Procedure
      • 9.3.1.2.4. By Treatment
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Acute Cholecystitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Cause
      • 9.3.2.2.3. By Diagnostic Procedure
      • 9.3.2.2.4. By Treatment
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Acute Cholecystitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Cause
      • 9.3.3.2.3. By Diagnostic Procedure
      • 9.3.3.2.4. By Treatment
      • 9.3.3.2.5. By End User

10. South America Acute Cholecystitis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Cause
  • 10.2.3. By Diagnostic Procedure
  • 10.2.4. By Treatment
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Acute Cholecystitis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Cause
      • 10.3.1.2.3. By Diagnostic Procedure
      • 10.3.1.2.4. By Treatment
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Acute Cholecystitis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Cause
      • 10.3.2.2.3. By Diagnostic Procedure
      • 10.3.2.2.4. By Treatment
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Acute Cholecystitis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Cause
      • 10.3.3.2.3. By Diagnostic Procedure
      • 10.3.3.2.4. By Treatment
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Acute Cholecystitis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boston Scientific Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Fresenius Kabi AG
• 15.3. Pfizer Inc
• 15.4. Teva Pharmaceutical Industries Ltd.
• 15.5. Glenmark Pharmaceuticals Limited
• 15.6. Merck & Co. Inc.
• 15.7. Becton, Dickinson and Company
• 15.8. Simulab Corporation
• 15.9. AbbVie Inc.
• 15.10. Fortimedix Surgical BV

16. Strategic Recommendations

17. About Us & Disclaimer